← Patent-cliff monitor small molecule LYNKUET ELINZANETANT
Loss of exclusivity May 2045 latest FDA-listed patent expiry
Drug detail Brand name LYNKUET Active ingredient ELINZANETANT Strength 60MG Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval October 2025 Marketing status RX
Listed patents Patent Expires Type 12533358 May 2045 use U-4402 12264164 March 2039 use U-3622 11787820 March 2039 use U-3622 10774091 March 2039 product 10195205 May 2036 use U-3622 7683056 September 2027 substance, product
Regulatory exclusivity Code Expires NCE October 2030
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.